Rockland Immunochemicals Awarded Phase I SBIR Funding to Develop Akt/mTOR Signaling Pharmacodynamics Assay

Published: Sep 28, 2010

GILBERTSVILLE, Pa.--(BUSINESS WIRE)--Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop a pharmacodynamic assay to monitor the Akt/mTOR signaling pathway.

Back to news